TLDR
- BioMarin climbs on $4.8B Amicus deal, adds rare disease assets to portfolio
- Voxzogo remains key driver as Amicus’s buy boosts long-term pipeline strength
- $59.43 close signals market confidence after BioMarin-Amicus merger news
- BioMarin gains two high-growth therapies in its $4.8B Amicus acquisition
- Analysts lift BioMarin target post-merger while long-term sales timeline holds
BioMarin Pharmaceutical Inc. (BMRN) closed at $59.43, gaining 0.75%, before dipping slightly to $59.35 in after-hours trading.
BioMarin Pharmaceutical Inc., BMRN
The intraday movement showed a minor early dip, followed by steady upward momentum with mild fluctuations throughout the session. The trading pattern reflects renewed interest after a major acquisition announcement that repositions BioMarin for long-term rare disease growth.
Amicus Acquisition Boosts Pipeline and Cash Flow Stability
BioMarin has agreed to acquire Amicus Therapeutics Inc. in an all-cash transaction valued at approximately $4.8 billion. The companies disclosed the deal on December 19, with BioMarin offering $14.50 per share for Amicus. The merger is expected to close by Q2 2026, pending regulatory clearance and shareholder approval.
The acquisition strengthens BioMarin’s rare disease portfolio by adding two high-revenue therapies, Galafold and Pombiliti + Opfolda. These treatments address Fabry and Pompe diseases, generating $599 million in combined revenue over the past year. Additionally, the deal secures U.S. rights to DMX-200, a Phase 3 therapy for a rare kidney disease.
This move expands BioMarin’s product base and enhances its late-stage pipeline. It provides short-term revenue growth and long-term market positioning in lysosomal storage disorders. The board of directors from both companies has unanimously approved the deal, signaling full internal support.
Voxzogo Continues to Drive Near-Term Performance
While the Amicus products bolster future earnings, Voxzogo remains BioMarin’s primary growth engine for now. Voxzogo, a treatment for achondroplasia, has shown strong uptake and revenue momentum across multiple regions. This therapy continues to support BioMarin’s quarterly performance and market valuation.
Analysts maintain that BioMarin’s reliance on Voxzogo will remain until the full integration of Amicus’s assets. Sales from acquired therapies may not reach their peak until the early 2030s. Therefore, BioMarin’s focus will likely remain on optimizing Voxzogo’s market reach in the short term.
Despite moderate expectations for near-term impact from the acquisition, the added assets reduce future cash flow uncertainty. BioMarin now holds a stronger balance between existing products and long-term pipeline growth. As a result, confidence in BioMarin’s revenue diversification has improved.
Analyst Sentiment and Market Outlook
On December 22, H.C. Wainwright raised BioMarin’s price target to $60 from $55 while keeping a Neutral rating. The firm highlighted that the Amicus deal stabilizes future revenue streams while reiterating that peak benefits lie years ahead. This revised outlook followed BioMarin’s strategic focus on expanding rare disease treatments.
The stock reacted positively to the news, reflecting investor alignment with BioMarin’s long-term strategy. While short-term upside remains modest, the acquisition strengthens the company’s position in the rare disease market. BioMarin’s increased scale and portfolio breadth could yield competitive advantages in regulatory and commercial domains.
Although Voxzogo remains the near-term anchor, the Amicus acquisition has positioned BioMarin for durable growth. With regulatory approvals and integration milestones ahead, market sentiment may shift as execution progresses. For now, BioMarin’s consistent movement signals cautious optimism around its future direction.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
